Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
5(19%)
Results Posted
13%(2 trials)
Terminated
2(8%)

Phase Distribution

Ph not_applicable
9
35%
Ph phase_3
2
8%
Ph phase_1
6
23%
Ph phase_4
2
8%
Ph phase_2
3
12%

Phase Distribution

6

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
6(27.3%)
Phase 2Efficacy & side effects
3(13.6%)
Phase 3Large-scale testing
2(9.1%)
Phase 4Post-market surveillance
2(9.1%)
N/ANon-phased studies
9(40.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

5

trials recruiting

Total Trials

26

all time

Status Distribution
Active(6)
Completed(15)
Terminated(2)
Other(3)

Detailed Status

Completed15
Recruiting4
unknown3
Terminated2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
5
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (27.3%)
Phase 23 (13.6%)
Phase 32 (9.1%)
Phase 42 (9.1%)
N/A9 (40.9%)

Trials by Status

terminated28%
not_yet_recruiting14%
unknown312%
active_not_recruiting14%
recruiting415%
completed1558%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT04002531Not Applicable

A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children

Completed
NCT06016569Not Applicable

Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.

Recruiting
NCT07079930Phase 1

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

Recruiting
NCT07372859Not Applicable

Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners

Not Yet Recruiting
NCT03534934Not Applicable

CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD

Completed
NCT07315893Not Applicable

Endoscopic Full Thickness Suturing of Mucosal, Submucosal and Perforation Defects Using Su2ura® GI System

Recruiting
NCT06003400Not Applicable

Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients

Active Not Recruiting
NCT06812221Phase 1

Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI

Completed
NCT06816667Phase 1

Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety

Completed
NCT04986917Not Applicable

Laparoscopic Ventral Hernia Repair with Routine Defect Closure Using Su2ura® Approximation Device

Completed
NCT05956314Phase 1

Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC

Completed
NCT05435638Phase 1

Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases

Completed
NCT06676410Phase 2

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

Recruiting
NCT05272969

Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease

Unknown
NCT05037162Phase 2

Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

Completed
NCT05576740

Influence of Menstrual Cycle Stages on Female Athletes

Completed
NCT04802382Phase 3

Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

Unknown
NCT04907162

Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders

Completed
NCT03691727Phase 1

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

Completed
NCT02412150Not Applicable

Effect of Dexmedetomidine After Thyroidectomy

Completed

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
26